Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine

[Red Phoenix]

 

Source: https://www.mdpi.com/2076-393X/13/6/553

 

= = =

 

Despite the findings (see below), the authors described the vaccine as “well tolerated.” 🤪

Below excerpts speak for themselves (bold added by me to highlight): 

3. Results

A total of 212 participants (51% male, n = 109) were screened between December 2021 and April 2022. Of these, 42 participants were enrolled, with 21 initially classified as seronegative and 21 as seropositive for SARS-CoV-2.

3.2. Other Adverse Events

Grade 3 or higher laboratory abnormalities were more frequent after the second vaccination than the first (39 vs. 9) (Table 3), with neutropenia, lymphopenia, and glucose abnormalities being most common. These abnormalities were more prevalent in the SARS-CoV-2 seropositive arm compared to the SARS-CoV-2 seronegative arm after both the first (7 vs. 2) and the second vaccinations (27 vs. 12), with notable differences in thrombocytopenia (first: 4 vs. 0; second: 8 vs. 0). None of the grade 3 or higher clinical AEs or laboratory abnormalities were attributed to the vaccine.